scholarly journals Correction: The Impact of Expanded Testing for Multidrug Resistant Tuberculosis Using Geontype MTBDRplus in South Africa: An Observational Cohort Study

PLoS ONE ◽  
2013 ◽  
Vol 8 (6) ◽  
Author(s):  
Colleen F. Hanrahan ◽  
Susan E. Dorman ◽  
Linda Erasmus ◽  
Hendrik Koornhof ◽  
Gerrit Coetzee ◽  
...  
Keyword(s):  
South Africa ◽  
Cohort Study ◽  
Multidrug Resistant ◽  
Observational Cohort Study ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Observational Cohort ◽  
The Impact

scholarly journals The Impact of Expanded Testing for Multidrug Resistant Tuberculosis Using Geontype MTBDRplus in South Africa: An Observational Cohort Study

PLoS ONE ◽  
2012 ◽  
Vol 7 (11) ◽  
pp. e49898 ◽  
Author(s):  
Colleen F. Hanrahan ◽  
Susan E. Dorman ◽  
Linda Erasmus ◽  
Hendrik Koornhof ◽  
Gerrit Coetzee ◽  
...  
Keyword(s):  
South Africa ◽  
Cohort Study ◽  
Multidrug Resistant ◽  
Observational Cohort Study ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Observational Cohort ◽  
The Impact

scholarly journals Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study

2016 ◽  
Vol 48 (5) ◽  
pp. 1496-1499 ◽  
Author(s):  
Polina A. Smirnova ◽  
Anna Turkova ◽  
Elena I. Nikishova ◽  
James A. Seddon ◽  
Elizabeth Chappell ◽  
...  
Keyword(s):  
Cohort Study ◽  
Multidrug Resistant ◽  
Observational Cohort Study ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Observational Cohort ◽  
Tuberculosis In Children

scholarly journals Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study

PLoS ONE ◽  
2016 ◽  
Vol 11 (11) ◽  
pp. e0164974 ◽  
Author(s):  
Rebecca Berhanu ◽  
Kathryn Schnippel ◽  
Erika Mohr ◽  
Kamban Hirasen ◽  
Denise Evans ◽  
...  
Keyword(s):  
South Africa ◽  
Cohort Study ◽  
Observational Cohort Study ◽  
Resistant Tuberculosis ◽  
Observational Cohort ◽  
Decentralized Care

scholarly journals Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured Versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study

Antibiotics ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 557
Author(s):  
Matthias Gijsen ◽  
Erwin Dreesen ◽  
Ruth Van Daele ◽  
Pieter Annaert ◽  
Yves Debaveye ◽  
...  
Keyword(s):  
Renal Function ◽  
Cohort Study ◽  
Protein Binding ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Observational Cohort Study ◽  
Target Attainment ◽  
Binding Model ◽  
Observational Cohort ◽  
The Impact

The impact of ceftriaxone pharmacokinetic alterations on protein binding and PK/PD target attainment still remains unclear. We evaluated pharmacokinetic/pharmacodynamic (PK/PD) target attainment of unbound ceftriaxone in critically ill patients with severe community-acquired pneumonia (CAP). Besides, we evaluated the accuracy of predicted vs. measured unbound ceftriaxone concentrations, and its impact on PK/PD target attainment. A prospective observational cohort study was carried out in adult patients admitted to the intensive care unit with severe CAP. Ceftriaxone 2 g q24h intermittent infusion was administered to all patients. Successful PK/PD target attainment was defined as unbound trough concentrations above 1 or 4 mg/L throughout the whole dosing interval. Acceptable overall PK/PD target attainment was defined as successful target attainment in ≥90% of all dosing intervals. Measured unbound ceftriaxone concentrations (CEFu) were compared to unbound concentrations predicted from various protein binding models. Thirty-one patients were included. The 1 mg/L and 4 mg/L targets were reached in 26/32 (81%) and 15/32 (47%) trough samples, respectively. Increased renal function was associated with the failure to attain both PK/PD targets. Unbound ceftriaxone concentrations predicted by the protein binding model developed in the present study showed acceptable bias and precision and had no major impact on PK/PD target attainment. We showed suboptimal (i.e., <90%) unbound ceftriaxone PK/PD target attainment when using a standard 2 g q24h dosing regimen in critically ill patients with severe CAP. Renal function was the major driver for the failure to attain the predefined targets, in accordance with results found in general and septic ICU patients. Interestingly, CEFu was reliably predicted from CEFt without major impact on clinical decisions regarding PK/PD target attainment. This suggests that, when carefully selecting a protein binding model, CEFu does not need to be measured. As a result, the turn-around time and cost for ceftriaxone quantification can be substantially reduced.

Multidrug-resistant tuberculosis in South Africa

The Lancet ◽  
1996 ◽  
Vol 348 (9042) ◽  
pp. 1658
Author(s):  
K Weyer ◽  
MF Stander
Keyword(s):  
South Africa ◽  
Multidrug Resistant ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis
Sign in / Sign up

Export Citation Format

Share Document